Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
-
Noosa News23 hours agoMan dies after stabbing in inner-city unit
-
Noosa News21 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General16 hours agoTribute unveiled for SA Police Brevet Sergeant Jason Doig after fatal 2023 shooting
-
General15 hours agoChinese spies, ports and Donald | Scam of the Week